Literature DB >> 33415079

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports.

Matthew D Tucker1, Kathryn E Beckermann1, Jennifer B Gordetsky2, Giovanna A Giannico2, Nancy B Davis1, Brian I Rini1.   

Abstract

Immunotherapy-based combinations have become standard of care in advanced renal cell carcinoma (RCC). Despite the potential for complete radiographic response, complete pathologic responses have been rarely reported. We present two cases of confirmed complete pathologic response to immunotherapy despite residual radiographic abnormalities. The first case describes a 68-year-old female with metastatic RCC who was treated with upfront pembrolizumab plus axitinib. She underwent nephrectomy after 15 doses of pembrolizumab with pathology revealing no evidence of viable tumor. To our knowledge, this is the first reported case of a complete pathologic response with pembrolizumab in metastatic RCC. The second case describes a 64-year-old female with metastatic RCC who was treated with second-line nivolumab after progression on cabozantinib. After 13 doses of nivolumab, she underwent nephrectomy with pathology revealing no evidence of viable tumor. These cases highlight the potential for scar tissue, fibrosis, and necrosis to persist radiographically after treatment with immunotherapy despite the absence of viable tumor cells.
Copyright © 2020 Tucker, Beckermann, Gordetsky, Giannico, Davis and Rini.

Entities:  

Keywords:  case reports; immunotherapy; kidney neoplasms; pathologic complete responders; pembrolizumab

Year:  2020        PMID: 33415079      PMCID: PMC7783360          DOI: 10.3389/fonc.2020.609235

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  16 in total

Review 1.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

2.  Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.

Authors:  Tomoki Okada; Shuzo Hamamoto; Toshiki Etani; Taku Naiki; Yasuhito Sue; Rika Banno; Kenji Yamada; Takeshi Sakakura; Takahiro Yasui
Journal:  Int Cancer Conf J       Date:  2020-03-13

3.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

5.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

6.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

7.  What is the role of nephrectomy following complete response to checkpoint inhibitors?

Authors:  Solomon L Woldu; James Brugarolas; Payal Kapur; Vitaly Margulis
Journal:  Urol Case Rep       Date:  2018-03-14

Review 8.  Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.

Authors:  Hsin-Yi Wang; Hueisch-Jy Ding; Jin-Hua Chen; Chih-Hao Chao; Yu-Yu Lu; Wan-Yu Lin; Chia-Hung Kao
Journal:  Cancer Imaging       Date:  2012-10-26       Impact factor: 3.909

9.  Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.

Authors:  Nirmish Singla; Roy Elias; Rashed A Ghandour; Yuval Freifeld; Isaac A Bowman; Leonid Rapoport; Mikhail Enikeev; Jay Lohrey; Solomon L Woldu; Jeffrey C Gahan; Aditya Bagrodia; James Brugarolas; Hans J Hammers; Vitaly Margulis
Journal:  Urol Oncol       Date:  2019-09-12       Impact factor: 2.954

10.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

Authors:  T K Choueiri; R J Motzer; B I Rini; J Haanen; M T Campbell; B Venugopal; C Kollmannsberger; G Gravis-Mescam; M Uemura; J L Lee; M-O Grimm; H Gurney; M Schmidinger; J Larkin; M B Atkins; S K Pal; J Wang; M Mariani; S Krishnaswami; P Cislo; A Chudnovsky; C Fowst; B Huang; A di Pietro; L Albiges
Journal:  Ann Oncol       Date:  2020-04-25       Impact factor: 32.976

View more
  3 in total

1.  Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma.

Authors:  Kazuki Shimizu; Satoshi Tamada; Yudai Matsuoka; Ishun Go; Satoshi Okumura; Masao Ogawa; Tetsuji Ohmachi
Journal:  Int Cancer Conf J       Date:  2022-04-19

2.  Complete Pathologic Response to Pembrolizumab and Axitinib in a Patient With Sarcomatoid RCC and Ocrelizumab-Treated Multiple Sclerosis.

Authors:  Kevin Neuzil; Kathryn Gessner; John Hedgepeth; Sara E Wobker; Eric M Wallen; Katherine P Morgan; Marc A Bjurlin; Tracy L Rose
Journal:  Urology       Date:  2021-12-29       Impact factor: 2.633

3.  Cabozantinib-Induced Severe Cardiac Dysfunction: A Case Report and a Systematic Review of the Literature.

Authors:  Chandan Buttar; Sofia Lakhdar; Mahmoud Nassar; Ian Landry; Most Munira
Journal:  Cureus       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.